Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]
In development [GID-TA10271] Expected publication date: TBC
Search results
584 results
-
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]
In development [GID-TA10449] Expected publication date: 19 April 2021
-
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
In development [GID-TA10575] Expected publication date: TBC
-
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal
In development [GID-NG10141] Expected publication date: 17 November 2021
-
Spasticity (after stroke) - botulinum toxin type A [ID768]
In development [GID-TAG499] Expected publication date: TBC
-
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
In development [GID-TA10105] Expected publication date: TBC
-
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017
-
Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
In development [GID-TA10527] Expected publication date: TBC
-
Secondary infection of common skin conditions including eczema: antimicrobial prescribing
In development [GID-NG10135] Expected publication date: 02 March 2021
-
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
In development [GID-TA10458] Expected publication date: 19 May 2021
-
Eculizumab for treating relapsing neuromyelitis optica [ID1271]
In development [GID-TA10469] Expected publication date: 02 September 2020
-
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
In development [GID-TA10313] Expected publication date: TBC
-
Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179
In development [GID-TA10450] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
In development [GID-HST10032] Expected publication date: TBC
-
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
In development [GID-TA10561] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]
In development [GID-TA10635] Expected publication date: TBC
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published date: 24 May 2019
-
Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]
In development [GID-TA10254] Expected publication date: TBC
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: TBC
-
Luspatercept for treating beta-thalassaemia ID1554
In development [GID-TA10506] Expected publication date: TBC
-
Kidney transplantation (rejection) - everolimus [ID117]
In development [GID-TAG241] Expected publication date: TBC
-
Selumetinib for treating differentiated thyroid cancer ID1079
In development [GID-TA10207] Expected publication date: TBC
-
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development [GID-TA10249] Expected publication date: TBC
-
NY-ESO-1 T-cells for treating synovial sarcoma ID1286
In development [GID-TA10205] Expected publication date: TBC
-
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development [GID-TA10251] Expected publication date: TBC
-
Eltrombopag for untreated severe aplastic anaemia ID1198
In development [GID-TA10284] Expected publication date: TBC
-
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis
In development [GID-DT9] Expected publication date: TBC
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Pembrolizumab with epacadostat for untreated malignant melanoma ID1423
In development [GID-TA10330] Expected publication date: TBC
-
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228
In development [GID-TA10203] Expected publication date: TBC
-
Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]
In development [GID-TA10149] Expected publication date: TBC
-
Bevacizumab for untreated malignant pleural mesothelioma (ID1183)
In development [GID-TA10197] Expected publication date: TBC
-
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
In development [GID-DT14] Expected publication date: TBC
-
Workplace health - older employees
In development [GID-PHG59] Expected publication date: 24 March 2016
-
Personal, social, health and economic education focusing on sex and relationships and alcohol education
In development [GID-PHG0] Expected publication date: TBC
-
Housing: planning to improve health and wellbeing
In development [GID-NG10053] Expected publication date: TBC
-
Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]
In development [GID-TAG321] Expected publication date: TBC
-
Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]
In development [GID-TA10168] Expected publication date: TBC
-
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]
In development [GID-HST10004] Expected publication date: TBC
-
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
In development [GID-TA10267] Expected publication date: TBC
-
Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]
In development [GID-TAG482] Expected publication date: TBC
-
Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250
In development [GID-TA10213] Expected publication date: TBC
-
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]
In development [GID-HST10007] Expected publication date: TBC
-
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
In development [GID-TAG507] Expected publication date: TBC
-
Pembrolizumab for previously treated multiple myeloma (ID1139)
In development [GID-TA10193] Expected publication date: TBC
-
Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]
In development [GID-TAG511] Expected publication date: TBC
-
Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]
In development [GID-TAG508] Expected publication date: TBC
-
Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]
In development [GID-TA10018] Expected publication date: TBC